Free Republic

Patients in clinical trials are usually faceless. But as the experimental Covid-19 vaccine being developed by Moderna Therapeutics has begun advancing through studies, it has found a much more visible advocate: trial volunteer Ian Haydon, a 29-year-old in Seattle. Haydon has spoken about the vaccine on CNN and CNBC. He even said he’d volunteer to be exposed to the novel coronavirus, SARS-CoV-2, if researchers want to test to see if the vaccine was actually effective. But up until now he has left out a key detail: He is, apparently, one of three people in the trial who had a systemic...

Data Published in Nature Biotechnology Show Messenger (m)RNA Prophylactic Vaccines Based on CureVac's RNActive® Technology Demonstrate Immunogenicity and Protection Against Influenza Virus Infection -- RNActive Vaccine Technology Allows Fast Production in Response to a Pandemic Scenario -- RNActive Vaccines Are Stable at High Temperatures Which Makes Them Suitable for Easy Worldwide Supply -- RNActive Vaccines May Become a Novel, Broadly Applicable and Easy-to-Handle Prophylactic Class of Vaccine Against Infectious Diseases TUEBINGEN, Germany, Nov. 25, 2012 /PRNewswire/ -- CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research...